title: [Graves' ophthalmopathy from the internist's perspective].
abstract: Graves' orbitopathy (GO) is the most frequently observed extrathyroidal manifestation of Graves' disease occurring in up to 40% of patients. Most patients with Graves' orbitopathy are tested positive for TSH receptor autoantibodies (TRAb), which are pathognomonic for Graves' disease and also play a central pathogenetic role in the development of GO. For the diagnosis of Graves' disease, symptoms of hyperthyroidism, low TSH and high fT3 and/or fT4 levels and positive TRAbs are typical. All patients with Graves' disease must be regularly examined for extrathyroidal manifestations, especially for Graves' orbitopathy. For hyperthyroidism, treatment with antithyroidal drugs, such as thiamazole or propylthiouracil is initiated to quickly restore euthyroidism, which also frequently leads to improvement of Graves' orbitopathy. Smoking cessation is also heavily mandated. In cases of relapse or ineffective antithyroidal treatment, radioiodine therapy or thyroid surgery is a further definitive therapeutic option to treat hyperthyroidism. The management of Graves' orbitopathy remains clinically challenging and demands involvement of a multidisciplinary team including endocrinologists, ophthalmologists, surgeons, radiotherapists and nuclear medicine specialists.
authors: Schwerpunkt Endokrinologie und Diabetologie, Abteilung Innere Medizin II, Universitätsklinikum Freiburg, Deutschland.
authors: K
authors: K
authors: Laubner
authors: W A
authors: WA
authors: Weber
authors: J
authors: J
authors: Seufert
references: Clin Endocrinol (Oxf). 2009 Oct;71(4):566-73
references: 19170704
references: Br J Ophthalmol. 2009 Aug;93(8):1052-6
references: 19221109
references: J Surg Res. 2000 May 15;90(2):161-5
references: 10792958
references: Med Klin (Munich). 2008 Oct 15;103(10):717-30; quiz 729-30
references: 18936897
references: Eur J Clin Invest. 1996 Jan;26(1):59-63
references: 8682157
references: Horm Metab Res. 2007 Jan;39(1):56-61
references: 17226115
references: World J Surg. 2008 Jul;32(7):1269-77
references: 18327526
references: Z Arztl Fortbild Qualitatssich. 2004 May;98 Suppl 5:55-62
references: 15255314
references: Eur Arch Otorhinolaryngol. 2010 Jun;267(6):955-60
references: 20035341
references: Med Klin (Munich). 2009 May 15;104(5):343-8
references: 19444414
references: Eur J Endocrinol. 2008 Jan;158(1):69-75
references: 18166819
references: Thyroid. 2002 Oct;12(10):855-60
references: 12487767
references: Exp Clin Endocrinol Diabetes. 2006 May;114(5):222-6
references: 16804795
references: Clin Endocrinol (Oxf). 2005 Oct;63(4):395-402
references: 16181231
references: Thyroid. 2000 Dec;10(12):1093-100
references: 11201855
references: N Engl J Med. 1998 Jan 8;338(2):73-8
references: 9420337
references: Curr Opin Endocrinol Diabetes Obes. 2008 Oct;15(5):446-52
references: 18769218
references: World J Surg. 2010 Jun;34(6):1261-4
references: 20033406
references: Clin Endocrinol (Oxf). 2000 Mar;52(3):267-71
references: 10718823
references: Eur J Clin Invest. 2009 Jan;39(1):51-7
references: 19087129
references: Clin Endocrinol (Oxf). 1995 Jan;42(1):45-50
references: 7889631
references: Internist (Berl). 2010 May;51(5):584, 586-8, 590-2, passim
references: 20383481
references: Am J Ophthalmol. 1996 Apr;121(4):426-34
references: 8604736
references: N Engl J Med. 1992 Jun 25;326(26):1733-8
references: 1489388
references: Clin Endocrinol (Oxf). 2007 Oct;67(4):607-12
references: 17880407
references: Am J Ophthalmol. 1995 Oct;120(4):511-7
references: 7573310
references: Dtsch Arztebl Int. 2009 Apr;106(17):283-9
references: 19547630